Xeris Biopharma Holdings Third Quarter 2023 Earnings: Beats Expectations

Xeris Biopharma Holdings (NASDAQ:XERS) Third Quarter 2023 Results

Key Financial Results

• Revenue: US$48.3m (up 63% from 3Q 2022).
• Net loss: US$12.2m (loss narrowed by 44% from 3Q 2022).
• US$0.088 loss per share (improved from US$0.16 loss in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xeris Biopharma Holdings Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 14% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Xeris Biopharma Holdings (including 1 which is a bit concerning).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.